New gut bacteria treatment for ulcerative colitis shows promise in early trial
Disease control
Terminated
This study tested an experimental treatment called VE202 in 114 people with mild-to-moderate ulcerative colitis. The goal was to see if VE202 could reduce inflammation in the colon and improve symptoms compared to a placebo. The trial was stopped early, but the results help resea…
Phase: PHASE2 • Sponsor: Vedanta Biosciences, Inc. • Aim: Disease control
Last updated May 17, 2026 03:32 UTC